The complete response letter cited issues with an active pharmaceutical ingredient used in the Biohaven 2017 bioequivalence study that was manufactured between 2014 and 2016 in an Apotex facility.
An overview of treatment guidelines and recommendations for managing patients with pediatric multiple sclerosis.

SAP Partner Banner